255 related articles for article (PubMed ID: 15689152)
1. Mechanism of CDK5/p25 binding by CDK inhibitors.
Mapelli M; Massimiliano L; Crovace C; Seeliger MA; Tsai LH; Meijer L; Musacchio A
J Med Chem; 2005 Feb; 48(3):671-9. PubMed ID: 15689152
[TBL] [Abstract][Full Text] [Related]
2. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
3. Structure and regulation of the CDK5-p25(nck5a) complex.
Tarricone C; Dhavan R; Peng J; Areces LB; Tsai LH; Musacchio A
Mol Cell; 2001 Sep; 8(3):657-69. PubMed ID: 11583627
[TBL] [Abstract][Full Text] [Related]
4. Structural Insights into Cdk5 activation by a neuronal Cdk5 activator.
Lim HY; Seow KT; Li Q; Kesuma D; Wang JH; Qi RZ
Biochem Biophys Res Commun; 2001 Jul; 285(1):77-83. PubMed ID: 11437375
[TBL] [Abstract][Full Text] [Related]
5. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
6. p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death.
Hamdane M; Bretteville A; Sambo AV; Schindowski K; Bégard S; Delacourte A; Bertrand P; Buée L
J Cell Sci; 2005 Mar; 118(Pt 6):1291-8. PubMed ID: 15741232
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
8. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
9. Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling.
Zhang J; Luan CH; Chou KC; Johnson GV
Proteins; 2002 Aug; 48(3):447-53. PubMed ID: 12112670
[TBL] [Abstract][Full Text] [Related]
10. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
Zheng YL; Li BS; Amin ND; Albers W; Pant HC
Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
[TBL] [Abstract][Full Text] [Related]
12. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
[TBL] [Abstract][Full Text] [Related]
14. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator.
Chou KC; Watenpaugh KD; Heinrikson RL
Biochem Biophys Res Commun; 1999 Jun; 259(2):420-8. PubMed ID: 10362524
[TBL] [Abstract][Full Text] [Related]
15. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity.
Tomizawa K; Ohta J; Matsushita M; Moriwaki A; Li ST; Takei K; Matsui H
J Neurosci; 2002 Apr; 22(7):2590-7. PubMed ID: 11923424
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.
Lin H; Juang JL; Wang PS
J Biol Chem; 2004 Jul; 279(28):29302-7. PubMed ID: 15123618
[TBL] [Abstract][Full Text] [Related]
17. Identification of functional domains in the neuronal Cdk5 activator protein.
Poon RY; Lew J; Hunter T
J Biol Chem; 1997 Feb; 272(9):5703-8. PubMed ID: 9038181
[TBL] [Abstract][Full Text] [Related]
18. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Brain Res Mol Brain Res; 2002 Oct; 106(1-2):50-6. PubMed ID: 12393264
[TBL] [Abstract][Full Text] [Related]
19. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
Kesavapany S; Zheng YL; Amin N; Pant HC
Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
[TBL] [Abstract][Full Text] [Related]
20. Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.
Zhang B; Tan VB; Lim KM; Tay TE; Zhuang S
J Mol Model; 2007 Jan; 13(1):79-89. PubMed ID: 16770643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
